Search

Displaying results 2391 - 2400 of 10000 in total
  1. Target

    ATP synthase F(0) complex subunit e, mitochondrial

    go.drugbank.com/bio_entities/BE0009021
    TargetHumans

    Part of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(0) complex subunit e, mitochondrialFunction: protein-containing complex binding
  2. Drug

    Diloxanide furoate

    go.drugbank.com/drugs/DB14638
    ApprovedInvestigational

    Synonyms: 2,2-dichloroacetamido-4-n-methylphenyl 2-furoate, 4-(n-methyl-2,2-dichloroacetamido)phenyl 2-furoate
  3. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

    Synonyms: N-methyl quinuclidinyl benzilateMixtures: LIBRAX DRAJE, 40 ADET, KLIPAKS DRAJE, 40 ADET
  4. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    [L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these

  5. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

    Mixtures: LONSURF FILM-COATED TABLET 20 MG/8.19 MG, LONSURF FILM-COATED TABLET 20 MG/8.19 MG
  6. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. … [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  8. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

    Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MGProducts: Naturetin 5mg
  9. Drug

    Dinalbuphine sebacate

    go.drugbank.com/drugs/DB15341
    Investigational

    Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

    Products: NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML
  10. Drug

    Metenolone

    go.drugbank.com/drugs/DB13710
    Investigational

    Products: RIMOBOLAN 100MG/1 ML ENJEKSIYONLUK COZELTI ICEREN AMPUL, 50 ADET, RIMOBOLAN 100MG/1 ML ENJEKSIYONLUK COZELTI ICEREN AMPUL, 100 ADET